BMC Cancer

Table 3 Serum content of vitamin D and correlations with survival endpoints

From: High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer

	T2–3 cases			T4 cases
25(OH)D, nmol/L	< 50	≥50	p ^a	< 50	≥50	p ^a
PFS
No. at risk	18	35		14	17
No. of events	4	12		9	6
Univariable HR (95% CI)	0.626	Referent	0.42	2.53	Referent	0.080
Univariable HR (95% CI)	(0.202–1.94)	Referent	0.42	(0.895–7.12)	Referent	0.080
Multivariable HR (95% CI)^b	0.720	Referent	0.59	3.09	Referent	0.048
Multivariable HR (95% CI)^b	(0.220–2.38)	Referent	0.59	(1.01–9.45)	Referent	0.048
OS
No. at risk	18	35		14	17
No. of events	2	5		7	1
Univariable HR (95% CI)	0.714	Referent	0.69	10.8	Referent	0.026
Univariable HR (95% CI)	(0.180–3.69)	Referent	0.69	(1.33–88.3)	Referent	0.026
Multivariable HR (95% CI)^b	0.783	Referent	0.79	17.6	Referent	0.010
Multivariable HR (95% CI)^b	(0.130–4.84)	Referent	0.79	(1.99–155)	Referent	0.010

Abbreviations: 25(OH)D 25-hydroxyvitamin D, CI confidence interval, HR hazard ratio, OS overall survival, PFS progression-free survival, T tumor stage
^aEstimated by Cox proportional hazards models
^bAdjusted for age, sex, body mass index, and season (winter/spring and summer/fall as collapsed categories)

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com